Tom Powles: Could sac-TMT Plus Pembrolizumab Improve First-Line Urothelial Cancer Outcomes?

Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:

“sac-TMT+pembro in 1st line UC shows increased efficacy (Fudan Uni ). It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD.

In 1st line UC it has 68% ORR , 1yr PFS and 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration.”